Genomics BioSci & Tech. Co.,Ltd. (TPEX:4195)
Taiwan
· Delayed Price · Currency is TWD 29.40
-0.60 (-2.00%)
Apr 29, 2026, 1:54 PM CST
Genomics BioSci & Tech. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 708.38 | 517.58 | 396.14 | 419 | 389.97 | Upgrade
|
| Revenue Growth (YoY) | 36.86% | 30.65% | -5.46% | 7.45% | -12.01% | Upgrade
|
| Cost of Revenue | 477.02 | 360.4 | 276.23 | 282.99 | 280.04 | Upgrade
|
| Gross Profit | 231.36 | 157.18 | 119.91 | 136.01 | 109.92 | Upgrade
|
| Selling, General & Admin | 223.48 | 207.53 | 148.47 | 131.79 | 121.69 | Upgrade
|
| Research & Development | 82.5 | 88.5 | 56.43 | 35.88 | 17.47 | Upgrade
|
| Operating Expenses | 315.52 | 297.47 | 201.81 | 169.53 | 138.58 | Upgrade
|
| Operating Income | -84.16 | -140.29 | -81.9 | -33.52 | -28.66 | Upgrade
|
| Interest Expense | -13.7 | -7.74 | -4.74 | -1.98 | -1.67 | Upgrade
|
| Interest & Investment Income | 2.11 | 2.37 | 2.09 | 0.35 | 0.27 | Upgrade
|
| Earnings From Equity Investments | - | -52.72 | -19.56 | -18.88 | -13.46 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.19 | 0.43 | 0.86 | 0.72 | -1.31 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.12 | 12.08 | 0.58 | 0.8 | 1.05 | Upgrade
|
| EBT Excluding Unusual Items | -95.68 | -185.87 | -102.67 | -52.5 | -43.78 | Upgrade
|
| Gain (Loss) on Sale of Investments | 25.14 | -47.06 | -65.29 | 124.76 | -9.31 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.89 | -1.06 | - | - | 65.18 | Upgrade
|
| Asset Writedown | - | -1.36 | - | - | - | Upgrade
|
| Other Unusual Items | 0.02 | 0 | 0.02 | - | 0.01 | Upgrade
|
| Pretax Income | -67.63 | -235.35 | -167.94 | 72.26 | 12.09 | Upgrade
|
| Income Tax Expense | - | - | 0.13 | 0.66 | - | Upgrade
|
| Earnings From Continuing Operations | -67.63 | -235.35 | -168.07 | 71.6 | 12.09 | Upgrade
|
| Net Income to Company | -67.63 | -235.35 | -168.07 | 71.6 | 12.09 | Upgrade
|
| Minority Interest in Earnings | 28.2 | 12.25 | - | - | 6.65 | Upgrade
|
| Net Income | -39.43 | -223.1 | -168.07 | 71.6 | 18.74 | Upgrade
|
| Net Income to Common | -39.43 | -223.1 | -168.07 | 71.6 | 18.74 | Upgrade
|
| Net Income Growth | - | - | - | 282.09% | 2927.14% | Upgrade
|
| Shares Outstanding (Basic) | 72 | 72 | 71 | 63 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 72 | 72 | 71 | 64 | 60 | Upgrade
|
| Shares Change (YoY) | - | 1.89% | 11.87% | 5.12% | 0.23% | Upgrade
|
| EPS (Basic) | -0.54 | -3.08 | -2.36 | 1.13 | 0.31 | Upgrade
|
| EPS (Diluted) | -0.54 | -3.08 | -2.36 | 1.13 | 0.31 | Upgrade
|
| EPS Growth | - | - | - | 267.48% | 3103.13% | Upgrade
|
| Free Cash Flow | -160.28 | -305.39 | -246.28 | -115.21 | -121.35 | Upgrade
|
| Free Cash Flow Per Share | -2.21 | -4.21 | -3.46 | -1.81 | -2.01 | Upgrade
|
| Dividend Per Share | - | - | - | 0.098 | - | Upgrade
|
| Gross Margin | 32.66% | 30.37% | 30.27% | 32.46% | 28.19% | Upgrade
|
| Operating Margin | -11.88% | -27.11% | -20.67% | -8.00% | -7.35% | Upgrade
|
| Profit Margin | -5.57% | -43.10% | -42.43% | 17.09% | 4.81% | Upgrade
|
| Free Cash Flow Margin | -22.63% | -59.00% | -62.17% | -27.50% | -31.12% | Upgrade
|
| EBITDA | -20.73 | -85.84 | -49.01 | -5.41 | 0.81 | Upgrade
|
| EBITDA Margin | -2.93% | -16.59% | -12.37% | -1.29% | 0.21% | Upgrade
|
| D&A For EBITDA | 63.43 | 54.45 | 32.89 | 28.1 | 29.47 | Upgrade
|
| EBIT | -84.16 | -140.29 | -81.9 | -33.52 | -28.66 | Upgrade
|
| EBIT Margin | -11.88% | -27.11% | -20.67% | -8.00% | -7.35% | Upgrade
|
| Effective Tax Rate | - | - | - | 0.92% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.